Literature DB >> 18819155

Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective.

Gladys P Agreda-Vásquez1, Irma Espinosa-Poblano, Sergio A Sánchez-Guerrero, Erick Crespo-Solís, Siram Cabrera-Vásquez, Josefa López-Salmorán, Josefina Barajas, Paula Peñaloza-Ramírez, Nelly Tirado-Cárdenas, Antonio Velázquez.   

Abstract

UNLABELLED: Therapeutic plasma exchange (TPE) is an effective treatment in Myasthenia gravis (MG) and Guillain-Barré syndrome (GBS) and 5% human albumin is the replacement fluid of choice; however, it is expensive. More recently, it has been suggested that starch is a safe and cheaper choice to human albumin.
OBJECTIVE: To evaluate our 5-year experience using 3% hydroxyethyl starch (HES) and 5% human albumin mixture, as replacement fluid in TPE for these diseases.
MATERIALS AND METHODS: Retrospective study carried out from January 2001 through September 2006. We included those patients with MG and GBS undergoing TPE. We analyzed clinical outcome (CO) and adverse events (AE) and our results were compared with a previous study which included similar patients undergoing TPE using just 5% human albumin.
RESULTS: Thirty-one procedures were carried out in 26 patients, a total of 147 TPE sessions. In the group of MG we had 57% complete responses (CR) and 86% overall response (OR) while in the group of GBS we had 40% CR and 60% OR. When we analyzed our CO with the previous study no statistical differences were found. Mean processed plasma volume (PPV) was 4.2 in MG and 5.5 in GBS. Twenty patients had AE, being hypotension and catheter dysfunction the most frequent ones, while tachycardia, hypertension and paresthesias were statistically more frequent in the HES/albumin group.
CONCLUSIONS: TPE with a mixture of 3% HES and 5% human albumin is as effective and safe as 5% human albumin alone for patients with these diseases. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18819155     DOI: 10.1002/jca.20175

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  3 in total

1.  Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases.

Authors:  David Aguirre-Valencia; Juan Naranjo-Escobar; Iván Posso-Osorio; María Carmenza Macía-Mejía; Ivana Nieto-Aristizábal; Tatiana Barrera; María Alejandra Obando; Gabriel J Tobón
Journal:  Autoimmune Dis       Date:  2019-03-11

2.  Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure.

Authors:  Jia Yao; Shuang Li; Li Zhou; Lei Luo; Lili Yuan; Zhongping Duan; Jun Xu; Yu Chen
Journal:  J Clin Apher       Date:  2019-02-13       Impact factor: 2.821

Review 3.  Plasma exchange in the intensive care unit: a narrative review.

Authors:  Philippe R Bauer; Marlies Ostermann; Lene Russell; Chiara Robba; Sascha David; Bruno L Ferreyro; Joan Cid; Pedro Castro; Nicole P Juffermans; Luca Montini; Tasneem Pirani; Andry Van De Louw; Nathan Nielsen; Julia Wendon; Anne C Brignier; Miet Schetz; Jan T Kielstein; Jeffrey L Winters; Elie Azoulay
Journal:  Intensive Care Med       Date:  2022-08-12       Impact factor: 41.787

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.